JeanFrancois Mouney - Genfit Chairman of the Management Board, CEO
| GNFT Stock | EUR 3.33 0.05 1.48% |
Chairman
Mr. JeanFrancois Mouney has served as Chairman of the Management Board and Chief Executive Officer of Genfit SA since 2008. Prior to this, he was Chairman of the Management Board of the Company between September 15, 1999 and 2008. He holds a Business Degree from the Paris Business School, and a degree in economics from the Universite Catholique de Lille. From 1979, he has created, managed and developed several companies specialised in high performance materials and in particular in the aeronautical industry. In 1992, he founded MM, a consultancy firm specialised in healthcare economy. He was responsible for carrying out a public feasibility study for an economic development agency in biologyhealthcare in the NordPasdeCalais region, and was appointed Managing Director of the agency when it was launched in 1995. actively involved from 1997 in the Companys incubation, he is cofounder of GENFIT, created in 1999. Chairman of the Management Board since that date, he received, in 2003 and again in 2004, the Entrepreneur of the Year award, organized internationally by Ernst Young, in the New Technology category. He is also Founder and Board Member of Naturalpha, a company created in 2001 specialised in Nutrition Research and Development and in clinical studies he is VicePresident of the research hub Nutrition, Health and Longevity since 2008.
| Age | 68 |
| Tenure | 17 years |
| Phone | (33) 3 20 16 40 01 |
| Web | www.genfit.com |
Genfit Management Efficiency
The company has return on total asset (ROA) of 0.1532 % which means that it generated a profit of $0.1532 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.6745 %, meaning that it generated $0.6745 on every $100 dollars invested by stockholders. Genfit's management efficiency ratios could be used to measure how well Genfit manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 4 records | CHAIRMAN Age | ||
| Herve Brailly | Innate Pharma | 62 | |
| Michel Rosen | DBV Technologies SA | 68 | |
| Gerard Soula | Adocia | 73 | |
| Andre Choulika | Cellectis | 58 | |
Management Performance
| Return On Equity | 0.67 | |||
| Return On Asset | 0.15 |
Genfit Leadership Team
Elected by the shareholders, the Genfit's board of directors comprises two types of representatives: Genfit inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genfit. The board's role is to monitor Genfit's management team and ensure that shareholders' interests are well served. Genfit's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genfit's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stefanie Magner, Chief Affairs | ||
| Pascal Caisey, Chief Officer | ||
| Dean Hum, COO, Chief Scientific Officer, Member of the Management Board | ||
| Thomas Baetz, Chief Officer | ||
| Pr Staels, CoFounder Board | ||
| JeanChristophe Marcoux, Chief Officer | ||
| Pascal Prigent, Chief Officer | ||
| Laurent Lannoo, Corp Affairs | ||
| Emilie Desodt, VicePres HR | ||
| JeanFrancois Mouney, Chairman of the Management Board, CEO |
Genfit Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genfit a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.67 | |||
| Return On Asset | 0.15 | |||
| Profit Margin | 0.51 % | |||
| Operating Margin | 0.48 % | |||
| Current Valuation | 30.62 M | |||
| Shares Outstanding | 49.82 M | |||
| Shares Owned By Insiders | 13.22 % | |||
| Shares Owned By Institutions | 2.47 % | |||
| Price To Earning | (18.01) X | |||
| Price To Book | 1.51 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Information and Resources on Investing in Genfit Stock
When determining whether Genfit is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Genfit Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Genfit Stock. Highlighted below are key reports to facilitate an investment decision about Genfit Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genfit. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Genfit Stock refer to our How to Trade Genfit Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.